Welcome to our dedicated page for Polyrizon SEC filings (Ticker: PLRZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Polyrizon Ltd. (PLRZ) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on the Nasdaq Capital Market. Polyrizon files reports on Form 20-F and Form 6-K under the Securities Exchange Act of 1934, and these documents offer insight into its development-stage biotechnology activities, financial condition, and corporate actions.
Recent Form 6-K filings incorporate press releases on key scientific and product milestones, such as preclinical results for PL-14 Allergy Blocker and PL-16 Viral Blocker, as well as data from the company’s intranasal naloxone hydrogel program within the Trap & Target™ platform. Other 6-K submissions include interim condensed financial statements, management’s discussion and analysis, and notices related to shareholder meetings and voting matters.
Filings also document capital structure and listing-related events. For example, Polyrizon has reported a reverse share split of its ordinary shares at a 1-for-6 ratio and has furnished a press release noting that it regained compliance with Nasdaq listing requirements. These disclosures help investors understand changes in share count, adjustments to warrants and options, and the company’s listing status.
Through Stock Titan, users can review Polyrizon’s 6-K reports and related exhibits, including financial statements, regulatory correspondence summaries, and scientific press releases that are incorporated by reference into registration statements on Form S-8 and Form F-3. AI-powered tools on the platform can assist in summarizing lengthy filings, highlighting key sections on topics such as product development, regulatory interactions with the FDA, and corporate approvals, helping readers navigate Polyrizon’s SEC reporting history more efficiently.
Polyrizon Ltd., a pre-clinical-stage biotech company focused on intranasal technologies, reported results from a comparative study of its naloxone nasal formulation against a commercial reference product. Using a validated silicone nasal cast model at the University of Parma’s Biopharmanet-TEC research center, the study evaluated where in the nose each product was deposited.
Polyrizon’s formulation showed significantly higher deposition in the highly vascularized upper/anterior nasal region, which is important for rapid systemic drug absorption. The company views these data as supporting its Trap & Target™ platform’s ability to control regional nasal deposition and is continuing to advance its naloxone program within a broader intranasal platform strategy.
Polyrizon Ltd. reported that it has signed a development agreement with Clearmind Medicine Inc. to create a proprietary intranasal formulation of MEAI, Clearmind’s non-hallucinogenic neuroplastogen drug candidate. The formulation is intended for treating addiction-related and other central nervous system conditions.
The collaboration uses Polyrizon’s intranasal delivery technology to advance an intranasal MEAI product that is expected to support Clearmind’s future clinical development programs. Polyrizon positions this deal as reinforcing its role as a partner for companies seeking specialized intranasal drug-delivery capabilities.
Polyrizon Ltd. has signed a non-binding Memorandum of Understanding to acquire a 51% stake in Arrow Aviation Ltd., a global private aviation company. Polyrizon plans to invest NIS 18,000,000 (approximately $5.8 million) in cash for this majority position on a fully diluted basis.
Arrow Aviation generates annual unaudited revenues of about $19 million and adjusted EBITDA of about $3 million, operating a fleet of executive jets and providing VIP, medical, government, and cargo aviation services. Ancillary arrangements include transferring a Hawker 800 aircraft valued at $3.5 million to Arrow Aviation in exchange for a Polyrizon convertible note, and converting Arrow’s shareholder debts into additional Polyrizon convertible notes so Arrow would have no institutional debt after closing.
The MOU also provides mutual call and put options on the remaining 49% of Arrow Aviation shares, exercisable after two years based on agreed valuation multiples, potentially leading to 100% ownership. A definitive agreement is expected within 30 days, subject to due diligence and customary closing conditions.
Polyrizon Ltd. filed a Form 6-K reporting the start of a key FDA-aligned usability (human factors) study for its lead product candidate, NASARIX™, an intranasal allergy blocker intended for broad consumer use. The study focuses on how users interact with the product, including labeling, instructions for use, and overall handling, to support future U.S. Food and Drug Administration review.
Successful completion is expected to provide important regulatory evidence for NASARIX readiness for clinical evaluation and represents a milestone toward Polyrizon’s planned clinical trials, which are expected to commence in Q3 2026. Polyrizon develops hydrogel-based nasal spray technologies designed to act as a protective barrier against viruses and allergens and to enable intranasal delivery of active drugs.
Polyrizon Ltd. reported that it has completed the branding process for its PL-14 allergy blocker, which will be marketed under the name NASARIX™. PL-14 is a pre-clinical intranasal product based on Polyrizon’s proprietary Capture and Contain™ hydrogel technology, designed to form a physical barrier in the nasal cavity against allergens and viruses.
The company conducted trademark screening and linguistic evaluations in the U.S. and European markets to support the new brand. Management describes NASARIX™ as an important step toward future commercialization and commercial readiness, with the product expected to be introduced in alignment with Polyrizon’s ongoing clinical progress and regulatory pathway.
Polyrizon Ltd. submitted a Form 6-K for December 2025, mainly to furnish a press release dated December 11, 2025. The press release is titled “Polyrizon Announces Promising Permeation Kinetics Supporting Advancement of Its Intranasal Naloxone Hydrogel Program,” highlighting progress in this intranasal treatment initiative.
Polyrizon Ltd. (PLRZ) is implementing a reverse share split of its ordinary shares at a 1-for-6 ratio, so every six existing ordinary shares will be consolidated into one new ordinary share. The company states that trading on the Nasdaq Capital Market on a split-adjusted basis will begin on November 28, 2025.
After the reverse split, the number of issued and outstanding ordinary shares will be adjusted from 6,250,053 to 1,041,676, while the authorized share capital will remain unchanged. Fractional shares will not be issued; fractions greater than 0.5 will be rounded up to the nearest whole share. The company will also make proportionate adjustments to the per share exercise price and the number of ordinary shares underlying all outstanding warrants and options.
Polyrizon Ltd. filed a Form F-3 shelf registration to offer and sell, from time to time after effectiveness, up to $50,000,000 of securities, including ordinary shares, warrants, and units. Each takedown will be detailed in a future prospectus supplement that sets pricing and specific terms.
The company may sell securities directly, through agents, dealers or underwriters, and may use methods such as at-the-market offerings, negotiated transactions, or block trades as described in its plan of distribution. Net proceeds will be used for general corporate purposes, including operations, capital expenditures, business and technology development, and potential strategic opportunities. Polyrizon’s ordinary shares trade on the Nasdaq Capital Market under PLRZ. Certain warrants may include 4.99% or 9.99% beneficial ownership limitations on exercise.
Polyrizon Ltd. furnished a Form 6-K that attaches a press release titled “Polyrizon Demonstrates Reversible Broad-Spectrum Viral Blocking by Its Intranasal Barrier-Forming Formulation.”
The filing states that the first four paragraphs of this press release are incorporated by reference into the company’s Registration Statements on Form S-8, to be part of those registrations from the date this report is submitted, to the extent not superseded by later filings.
Polyrizon Ltd. furnished a Form 6-K as a foreign private issuer, providing a press release dated October 6, 2025. The release is titled “Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy,” indicating that PL-14 showed encouraging allergen-blocking performance in pre-clinical testing. The first five paragraphs of this press release are expressly incorporated by reference into Polyrizon’s effective employee equity Registration Statements on Form S-8, making the scientific update part of those registration statements from the date of this filing.